Abbvie

Skyrizi

Manufacturer:

Abbvie

Skyrizi HCPCS:

J2327

HCPCS Code Descriptor:

Injection, risankizumab-rzaa, intravenous, 1 mg

Category:

J Code

Skyrizi NDCs:

00074-1070-01, 00074-5015-01, 00074-1065-01, 00074-2100-01, 00074-1050-01

Primary Type:

Immunology:Anti-TNF

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Skyrizi:

Skyrizi is an Immunology:Anti-TNF drug manufactured by Abbvie and administered via the Subcutaneous route of administration. The J Code: J2327 is aligned to the drug Skyrizi.

SKYRIZI is a monoclonal antibody used to treat Crohn’s disease, psoriatic arthritis, and plaque psoriasis. It acts by binding to interleukin-23 (IL-23) and limiting its interaction with the IL-23 receptor, inhibiting the release of pro-inflammatory cytokines and chemokines that IL-23 stimulates. SKYRIZI (J2327) is used to treat older adults with plaque psoriasis and psoriatic arthritis and is more commonly used to treat younger adults with Crohn’s disease. Patient assistance for this medication can be found through AbbVie.

ACCESS PRICING AND MORE BY REGISTERING

J2327 Added Date:

January 1, 2023

J2327 Effective Date:

January 1, 2023

J2327 Termination Date:

HCPCS Active

Skyrizi billing and coding information can be found through Abbvie at the link below:
Skyrizi patient assistance information can be found through myAbbvie Assist at the URL: https://www.abbvie.com/patients/patient-assistance.html
Skyrizi prescribing information can be found at the link below:
Information regarding Skyrizi’s side effects can be found at MedlinePlus